CSIMarket
 
Tonix Pharmaceuticals Holding Corp   (TNXP)
Other Ticker:  
 
 
Price: $0.3210 $-0.01 -3.401%
Day's High: $0.3491 Week Perf: -11.35 %
Day's Low: $ 0.32 30 Day Perf: -16.84 %
Volume (M): 1,640 52 Wk High: $ 2.24
Volume (M$): $ 526 52 Wk Avg: $0.82
Open: $0.35 52 Wk Low: $0.26



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -117
 Cash Flow (TTM) (Millions $) -111
 Capital Exp. (TTM) (Millions $) 15

Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological disorders. The company's lead product candidate, TNX-102 SL, is a sublingual tablet formulation of cyclobenzaprine being developed for the treatment of posttraumatic stress disorder (PTSD), fibromyalgia, and agitation in Alzheimer's disease. Tonix also has a pipeline of other product candidates targeting conditions such as migraine, cocaine dependence, and tick-borne diseases. The company utilizes a proprietary platform technology called Tonix Translational Medicine (TTM) to design new drug products with improved safety, efficacy, and pharmacokinetic properties.


   Company Address: 26 Main Street Chatham 7928 NJ
   Company Phone Number: 799-9155   Stock Exchange / Ticker: NASDAQ TNXP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Illuminating the Path: Tonmya's Breakthrough in Alleviating Fibromyalgia Brain Fog and Pain Opens New Horizons

Published Mon, Mar 11 2024 12:01 PM UTC

aims to explore groundbreaking developments in the field of pharmaceutical research. This article highlights the significant findings from the RESILIENT Phase 3 Clinical Trial, conducted by Tonix Pharmaceuticals, regarding the efficacy of Tonmya in reducing brain fog and pain in fibromyalgia patients. We will outline the key facts and assess their impact on the company's fu...

Clinical Study

Tonix Pharmaceuticals Enhances Treatment for PTSD, Expands Reach in Asian Market, and Offers Hope for Fibromyalgia Patients

Published Thu, Mar 7 2024 1:00 PM UTC

Tonix Pharmaceuticals Making Strides in PTSD, Asian Market, and Fibromyalgia TreatmentTonix Pharmaceuticals, a leading biopharmaceutical company focused on researching and developing innovative medications for challenging conditions, has recently made significant breakthroughs in the treatment of post-traumatic stress disorder (PTSD), expansion into the Asian market, and the...

Partnership

Collaboration between Tonix Pharmaceuticals and EVERSANA: A Promising Step towards Effective Fibromyalgia Management.

Published Wed, Mar 6 2024 1:01 PM UTC

Tonix Pharmaceuticals, a biopharmaceutical company focusing on the development and commercialization of innovative therapies, recently announced its collaboration with EVERSANA for the launch strategy and commercialization planning for Tonmya. The drug, being developed as a potential first-line treatment for fibromyalgia, is a centrally acting non-opioid analgesic with promi...

Clinical Study

A Pathway to Prevention: TNX-1500's Potential in Reducing Kidney Transplant Rejection

Published Wed, Feb 28 2024 1:01 PM UTC

Tonix Pharmaceuticals Progresses in the Development of TNX-1500 and Its Potential Impact on Kidney Transplant RejectionWith the increasing demand for organ transplantation worldwide, finding effective ways to prevent graft rejection is crucial. Tonix Pharmaceuticals recently completed the clinical stage of its Phase 1 trial for TNX-1500, a promising Fc-modified humanized ant...

Clinical Study

Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya Support Development and Partnering in Japan and China

Published Tue, Feb 27 2024 1:01 PM UTC

Tonix Pharmaceuticals recently announced positive results from a clinical pharmacokinetic bridging study of Tonmya, a potential treatment for posttraumatic stress disorder (PTSD). The study aimed to support the development and partnering of Tonmya in Japan and China. The company plans to file a Clinical Trial Notification (CTN) in Japan and an Investigational New Drug (IND) ...






 

Tonix Pharmaceuticals Holding's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com